Q3 2024 Earnings Forecast for Ironwood Pharmaceuticals, Inc. Issued By Leerink Partnrs (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Research analysts at Leerink Partnrs issued their Q3 2024 earnings per share estimates for Ironwood Pharmaceuticals in a report released on Monday, September 9th. Leerink Partnrs analyst F. Khurshid anticipates that the biotechnology company will earn $0.03 per share for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q4 2024 earnings at $0.09 EPS, Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.04 EPS and FY2025 earnings at $0.13 EPS.

Several other equities research analysts have also weighed in on IRWD. Capital One Financial lowered shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. StockNews.com raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 16th. Wells Fargo & Company reduced their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. Craig Hallum dropped their target price on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Finally, Leerink Partners began coverage on Ironwood Pharmaceuticals in a research note on Monday. They issued a “market perform” rating and a $5.00 target price on the stock. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.57.

Ironwood Pharmaceuticals Stock Performance

Ironwood Pharmaceuticals stock opened at $4.53 on Wednesday. Ironwood Pharmaceuticals has a 1 year low of $3.79 and a 1 year high of $15.70. The firm’s 50-day moving average is $5.58 and its 200-day moving average is $6.96. The company has a market cap of $709.08 million, a P/E ratio of -0.67 and a beta of 0.49.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in IRWD. CWM LLC raised its stake in shares of Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after buying an additional 2,345 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Ironwood Pharmaceuticals by 152.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 2,645 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Ironwood Pharmaceuticals by 344.1% in the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 8,156 shares during the last quarter. First Dallas Securities Inc. bought a new position in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at about $73,000. Finally, SG Americas Securities LLC acquired a new position in shares of Ironwood Pharmaceuticals in the 1st quarter worth approximately $91,000.

Insiders Place Their Bets

In related news, insider Minardo John sold 9,910 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $4.27, for a total value of $42,315.70. Following the completion of the sale, the insider now owns 284,661 shares of the company’s stock, valued at $1,215,502.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.90% of the stock is currently owned by insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.